StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Hold

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday. Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th. View Our […]

Leave a Reply

Your email address will not be published.

Previous post Immigration front and center: Trump names key figures for incoming administration 
Next post MannKind (NASDAQ:MNKD) Upgraded to “Buy” at StockNews.com